Zymeworks (ZYME) Cash & Equivalents (2021 - 2026)

Zymeworks (ZYME) has 6 years of Cash & Equivalents data on file, last reported at $244.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 220.56% year-over-year to $244.3 million; the trailing twelve-month figure through Mar 2026 stood at $244.3 million (up 220.56% YoY), and the FY2025 full-year result was $41.2 million, down 37.74% from the prior year.
• Cash & Equivalents advanced to $244.3 million in Q1 2026, from $41.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $400.9 million in Q4 2022 to a low of $41.2 million in Q4 2025.
• A 5-year average of $131.4 million and a median of $98.3 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents tumbled 60.7% in 2023 and surged 220.56% in 2026, its largest moves.
• Tracing ZYME's Cash & Equivalents over 5 years: stood at $400.9 million in 2022, then plunged by 60.7% to $157.6 million in 2023, then plunged by 58.05% to $66.1 million in 2024, then sank by 37.74% to $41.2 million in 2025, then surged by 493.54% to $244.3 million in 2026.
• Business Quant data shows ZYME's Cash & Equivalents at $244.3 million in Q1 2026, $41.2 million in Q4 2025, and $64.8 million in Q3 2025.